Withdrawn: Biogen sent draft proxy insert addressing shareholder resolutions. Shareholders withdrew the proposal.
Proposal to request the Compensation and Management Development Committee of the board of directors publish a report assessing the feasibility of incorporating public concern over high drug prices into the senior executive compensation arrangements described in Biogen’s annual proxy materials.
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes. You can consent to the use of such technologies by using the “Accept” button, by closing this notice, by scrolling this page, by interacting with any link or button outside of this notice or by continuing to browse otherwise.